Article | 3 July 2012 Print This ShareThis Taiwan based active pharmaceutical ingredients maker ScinoPharm (TWSE: 1789) says it plans to invest NT$1.1 billion (around $37.6 million) in the construction of a high potency cytotoxic injectable plant suitable for production of oncological injectable products at the company's premises on the Tainan Science Park. ScinoPharm say it currently has the most number of oncological APIs for the generic industry. "By expanding into the field of oncological injectable formulation, ScinoPharm will be able to provide a vertically integrated, one-stop-shop service for our existing API customers," remarked Jo Shen, president and chief executive of the company. Enjoying this article? Have the leading Biopharma news & analysis delivered daily on email by signing up for our FREE email newsletter here. Current demand of oncology injectables exceeds supply "The global demand for oncological injectable production capacity far exceeds the supply. Many international generic customers of ours have been eagerly searching for partners who can provide a high quality and stable supply of oncological injectable drug products not to mention meet GMP requirements," Dr Shen added. The entire facility will include space for R&D, quality control, washing, sterilization, manufacturing, filling, lyophilization, packaging, and storage. There will be one line for the oncological production, capable for producing liquid vials as well as lyophilized vials. In a separate, isolated area, there will also be equipment for prefilled syringes dedicated for non-cytotoxic products. This special capability was added again as a response to the severe shortage of capacity in the market. The entire injectable plant will meet the international cGMP standards of the sterile facility. For the cytotoxic area, where high potency oncological products will be produced, sophisticated containment equipment will be installed with proper safety protection, the company noted. Design and construction of the plant is expected to begin in the second half of 2012, with completion expected in 2014. ScinoPharm's main objective is to provide value-added services to the existing customers through contract manufacturing services of oncological injectable form. Through the expanded capabilities, ScinoPharm hopes to further solidify its leadership position in the oncological area with enhance support to its customers.
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment